<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1819_S12_C19_p371-380</title>
		<link href="BCSC1819_S12_C19_p371-380-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1819_S12_C19_p371-380" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="part-title">Selected <br />Therapeutic <br />Topics</p>
		</div>
		<div id="_idContainer001" class="Basic-Text-Frame">
			<p class="part-number">PART III</p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer003" class="_idGenObjectStyleOverride-2">
			</div>
		</div>
		<div id="_idContainer004" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter</span><span class="cn-chap"> </span>19</p>
			<p class="chapter-title">Laser Therapy for Posterior Segment Diseases</p>
			<p class="h1 ParaOverride-1">Basic Principles of Photocoagulation</p>
			<div id="Chapt19_Top1">
			<p class="body-text--no-indent-">Photocoagulation uses light energy to coagulate tissue. &#173;After light energy is applied to the target tissue, it converts into thermal energy, and the tissue temperature rises above 65°C, causing denaturation of tissue proteins and coagulative necrosis.</p>
			<p class="body-text">Current posterior segment &#173;laser delivery systems span the vis&#173;i&#173;ble light spectrum of 400–700&#160;nm (green, yellow, red) and venture into the infrared wavelengths (<span class="symbol">&gt;</span>700&#160;nm). Delivery systems may employ a transpupillary approach with slit-&#173;lamp or indirect ophthalmoscopic delivery, endophotocoagulation during vitrectomy, or transscleral application with a contact probe.</p>
			<p class="body-text">The effectiveness of photocoagulation depends on the transmission of light through ocular media and the absorption of that light by pigment in the target tissue. Light is absorbed principally by ocular tissues that contain melanin, xanthophyll, or hemoglobin. <span class="xref-figure">Figure&#160;19-1</span> illustrates the absorption spectra of the key pigments found in ocular tissues:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-2"><span class="italic">Melanin</span> is an effective absorber of green, yellow, red, and infrared wavelengths.</li>
				<li class="bullet-list-mid ParaOverride-2">Macular <span class="italic">xanthophyll</span> readily absorbs blue but minimally absorbs yellow and red wavelengths.</li>
				<li class="bullet-list-mid"><span class="italic">Hemoglobin</span> easily absorbs blue, green, and yellow but has minimal absorption of red wavelengths.</li>
			</ul>
			<p class="h2">Choice of &#173;Laser Wavelength</p>
			<p class="body-text--no-indent-">&#173;Laser wavelength se&#173;lection depends on the specific goals of treatment and the degree to which the photocoagulation must be targeted to the par&#173;tic&#173;u&#173;lar tissue while sparing adjacent healthy tissue. The <span class="italic">area</span> (depth and dia&#173;meter) of effective coagulation is directly related to the <span class="italic">intensity</span> and <span class="italic">duration</span> of irradiation. For a specific set of &#173;laser par&#173;ameters (spot size, duration, and power), the intensity of the burn obtained depends on the clarity of the ocular media and the degree of pigmentation.</p>
			<p class="body-text">The <span class="italic">green &#173;laser</span> produces light that is absorbed well by melanin and hemoglobin and less completely by xanthophyll. &#173;Because of &#173;these characteristics and the absence of undesirable short (blue) wavelengths, the green &#173;laser has replaced the blue-&#173;green &#173;laser for treatment of ret&#173;i&#173;nal vascular abnormalities and choroidal neovascularization (CNV).</p>
			<p class="body-text">The <span class="italic">red &#173;laser</span> penetrates through nuclear sclerotic cataracts and moderate vitreous hemorrhages better than &#173;lasers with other wavelengths do. In addition, it is minimally absorbed by xanthophyll and thus may be useful in treatments near the fovea. The red &#173;laser &#173;causes deeper burns with a higher rate of patient discomfort and inhomogeneous absorption at the level of the choroid. The <span class="italic">infrared &#173;laser</span> has characteristics similar to &#173;those of the red &#173;laser with even deeper tissue penetration.</p>
			<p class="body-text">The <span class="italic">yellow &#173;laser</span> has, among its advantages, minimal scatter through nuclear sclerotic lenses, low xanthophyll absorption, and &#173;little potential for photochemical damage. It appears to be useful for destroying vascular structures while causing minimal damage to adjacent pigmented tissue; thus, it may be valuable for treating ret&#173;i&#173;nal vascular and choroidal neovascular lesions. For typical &#173;laser wavelengths of specific &#173;lasers, see BCSC Section&#160;3, <span class="italic">Clinical Optics,</span> Chapter&#160;2.</p>
			<p class="body-text">&#173;Laser effects on posterior segment tissues include photochemical and thermal effects and vaporization. Photochemical reactions can be induced by ultraviolet or vis&#173;i&#173;ble light that is absorbed by tissue molecules or by molecules of a photosensitizing medi&#173;cation (eg, verteporfin), producing cytotoxic reactive oxygen species (eg, &#173;free radicals). Absorption of &#173;laser energy by pigment results in a temperature rise by tens of degrees and subsequent protein denaturation; the exact temperature rise depends on &#173;laser wavelength, &#173;laser power, duration of &#173;laser application, and spot size. Vaporization is generated by the rise in &#173;water temperature above the boiling point, which &#173;causes microexplosions, as can occur in overly intense burns. For further discussion of &#173;laser light characteristics and light–&#173;tissue interactions, see BCSC Section&#160;3, <span class="italic">Clinical Optics,</span> Chapter&#160;2.</p>
			<p class="reference--non-journal--first">Atebara NH, Thall EH. Princi&#173;ples of &#173;lasers. In: Yanoff M, Duker JS. <span class="italic">Ophthalmology.</span> 4th&#160;ed. Philadelphia: Elsevier/Saunders; 2014:32–37.</p>
			<p class="reference--non-journal--last">Palanker D, Blumenkranz MS. Ret&#173;i&#173;nal &#173;laser therapy: biophysical basis and applications. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, eds. <span class="italic">Ryan’s</span> <span class="italic">Ret&#173;i&#173;na.</span> Vol 1. 6th&#160;ed. Philadelphia: Elsevier/Saunders; 2018:chap 41.</p>
			<p class="h2">Practical Aspects of &#173;Laser Photocoagulation</p>
			<p class="h3-h2">Anesthesia</p>
			<p class="body-text--no-indent-">Topical, peribulbar, or retrobulbar anesthesia may be needed to facilitate delivery of &#173;laser photocoagulation. The risks of peribulbar and retrobulbar injection should be considered when choosing among &#173;these forms of anesthesia.</p>
			<p class="h3">Lenses</p>
			<p class="body-text--no-indent-">Two types of contact lenses are available to assist in slit-&#173;lamp delivery of photocoagulation:</p>
			<p class="numbered-list-first">1.&#9;negative-&#173;power planoconcave lenses</p>
			<p class="numbered-list-last">2.&#9;high-&#173;plus-&#173;power lenses</p>
			<p class="body-text--no-indent-">The planoconcave lenses provide an upright image with superior resolution of a small ret&#173;i&#173;nal area. Most clinicians &#173;favor use of &#173;these lenses for macular treatments. Mirrored planoconcave lenses facilitate viewing and photocoagulation of more peripheral ret&#173;i&#173;na; the exact location in view depends on the &#173;angle of the mirror used. Planoconcave lenses generally provide the same ret&#173;i&#173;nal spot size as that selected on the slit-&#173;lamp setting.</p>
			<p class="body-text">High-&#173;plus-&#173;power lenses provide an inverted image with some loss of fine resolution, but they offer a wide field of view, which facilitates efficient treatment over a broad area. The macula may be kept in view while the midperiphery of the ret&#173;ina is being treated, making &#173;these lenses ideal for panret&#173;i&#173;nal photocoagulation. High-&#173;plus-&#173;power lenses provide a spot size that is magnified over the &#173;laser setting size; the magnification &#173;factor depends on the lens used (<span class="xref-table">&#173;Table&#160;19-1</span>).</p>
			<p class="h3">Par&#173;ameters and indications</p>
			<p class="body-text--no-indent-">Se&#173;lection of &#173;laser setting par&#173;ameters depends on the treatment goals, the clarity of the ocular media, and the fundus pigmentation. As a general rule, smaller spot sizes require less energy than larger spot sizes, and longer-&#173;duration exposures require less energy than shorter-&#173;duration exposures to achieve the same intensity effects. The following sections pres&#173;ent guidelines for conventional &#173;laser treatments.</p>
			<p class="h4-text"><span class="h4-head">Macular &#173;laser</span> Although its use is declining, &#173;laser photocoagulation still has a role in the management of some forms of macular edema, extrafoveal CNV, and focal ret&#173;i&#173;nal pigment epithelium (RPE) abnormalities with leakage, such as &#173;those seen in central serous chorioretinopathy. To avoid causing central scotomas and perifoveal capillary dropout, treatment should not be administered within 500 µm of the foveal center. Macular &#173;laser treatment for edema generally employs a smaller spot size (50–200 µm) and shorter duration (<span class="symbol">≤</span>0.1 second) to achieve smaller, less-&#173;intense burns. For diabetic macular edema, green or yellow direct &#173;laser therapy should be applied to all leaking microaneurysms located between 500 µm and 3000 µm from the center of the macula. For more diffuse leakage or zones of capillary nonperfusion, a light-&#173;intensity grid pattern using a green or yellow &#173;laser is applied to all areas of diffuse leakage more than 500 µm from the center of the macula and 500 µm from the temporal margin of the optic nerve head. A similar strategy is employed in treating macular edema caused by branch ret&#173;i&#173;nal vein occlusion. In the treatment of CNV or RPE leakage spots, the aim is to achieve a more intense burn of the entire lesion or area of leakage.</p>
			<p class="h4-text"><span class="h4-head">Peripheral ret&#173;i&#173;nal photocoagulation</span> Peripheral ret&#173;i&#173;nal photocoagulation may be delivered with &#173;either a slit-&#173;lamp or indirect ophthalmoscopic delivery system. The latter system offers less control over precise spot size or burn intensity. In panret&#173;i&#173;nal photocoagulation (PRP) or &#173;laser retinopexy, the aim is to achieve somewhat intense, larger &#173;laser burns. For PRP, the &#173;laser spot size typically is 200–500 µm, and &#173;laser power is adjusted to achieve gray or light cream-&#173;colored burns. Applications, or burns, are usually one-&#173;half to one burn width apart (see <span class="xref-figure-local">Chapter&#160;5, Fig 5-8</span>) and should spare the macula. For initial PRP treatment, some prac&#173;ti&#173;tion&#173;ers leave approximately 1–2 disc dia&#173;meters of ret&#173;ina outside of the macula and optic nerve head untreated, whereas &#173;others treat up to the arcade vessels and up to the optic nerve (<span class="xref-figure">Fig 19-2</span>). The initial treatment pattern can be concentrated more densely in the inferior ret&#173;ina to help minimize temporal and inferior visual field loss and to facilitate retreatment in the case of vitreous hemorrhage. The long ciliary nerves in the 3-&#173; and 9-&#173;o’clock meridians should be avoided, if pos&#173;si&#173;ble, and any coexisting macular edema should be treated beforehand to avoid exacerbation &#173;after PRP. Typically, 1200–1400 &#173;laser applications of 500-&#173;µm spot size—&#173;the equivalent of smaller burns—&#173;are placed.</p>
			<p class="h4-text">&#173;Laser retinopexy is used to create a chorioret&#173;i&#173;nal adhesion around ret&#173;i&#173;nal tears or for demarcation of a (small) ret&#173;i&#173;nal detachment; it uses spot sizes of 200–500 µm, and its goal is creating whitish, but not snow-&#173;white, burns. Usually, 2–3 rows of photocoagulation around the break are considered appropriate to achieve the desired adhesion.</p>
			<p class="h4-text"><span class="h4-head">&#173;Laser ablation of ret&#173;i&#173;nal vascular lesions</span> Vascular lesions are often treated using a large spot size (<span class="symbol">≥</span>500 µm), lower power, and long duration so each lesion slowly heats up and coagulates “from the inside out.” High-&#173;intensity burns whiten the surface of the lesions, &#173;after which visible-&#173;light &#173;laser does not penetrate well, making it difficult to achieve the treatment goal.</p>
			<p class="h3">Alternative &#173;laser delivery systems and strategies</p>
			<p class="body-text--no-indent-">New technologies and concepts have led to novel treatment systems and strategies. Recent innovations in slit-&#173;lamp delivery systems include pattern scanners that deliver an entire array of &#173;laser applications with each foot-&#173;pedal depression; the high-&#173;intensity &#173;laser pulses are ultrashort (20–50 milliseconds) and are delivered in rapid succession. This approach possibly increases the efficiency of treatment, but it may not achieve an effect equivalent to traditional &#173;laser treatment on a spot-&#173;number-&#173;to-&#173;spot-&#173;number comparison.</p>
			<p class="body-text">Some systems incorporate real-&#173;time ret&#173;i&#173;nal image overlay and registration with the &#173;laser delivery system. This configuration allows for computer-&#173;assisted planning and precise targeting of the ret&#173;i&#173;nal lesions during treatments.</p>
			<p class="body-text">Delivery systems that apply subthreshold (barely vis&#173;i&#173;ble to invisible) &#173;laser spots administer &#173;laser in micropulses (<span class="symbol">≤</span>0.1 millisecond) that can confine heat conduction to the RPE while limiting thermal damage to the photoreceptors and choriocapillaris. &#173;These systems have been shown to be effective in treating diabetic macular edema and have the potential to reduce the number and size of scotomas. Titration of burn intensity and monitoring of the area of placement of invisible &#173;laser spots during &#173;laser delivery is enhanced in commercial &#173;laser systems using endpoint software technology.</p>
			<p class="reference--non-journal--first">Baumal CR, Ip M, Puliafito CA. Light and &#173;laser injury. In: Yanoff M, Duker JS. <span class="italic">Ophthalmology.</span> 4th&#160;ed. Philadelphia: Saunders/Elsevier; 2013:461–466.</p>
			<p class="reference--journal--mid">Chappelow AV, Tan K, Waheed NK, Kaiser PK. Panret&#173;i&#173;nal photocoagulation for proliferative diabetic retinopathy: pattern scan &#173;laser versus argon &#173;laser. <span class="italic">Am J Ophthalmol.</span> 2012;153(1):137–142.e2.</p>
			<p class="h2 ParaOverride-3">Complications of Photocoagulation</p>
			<p class="body-text--no-indent-">The most serious complications of photocoagulation are caused by the use of excessive energy or misdirected light. Complications that may be associated with photocoagulation include inadvertent corneal burns, which can lead to opacities. Treatment of the iris may cause iritis and create zones of atrophy. Pupillary abnormalities may arise from thermal damage to the long ciliary nerves in the suprachoroidal space or the iris sphincter muscle. Absorption by lens pigments may create lenticular burns and resultant opacities. Optic neuropathy may occur from treatment directly to or adjacent to the optic nerve head, and nerve fiber damage may follow intense absorption in zones of intraret&#173;i&#173;nal hemorrhage, increased pigmentation, or ret&#173;i&#173;nal thinning. Chorioret&#173;i&#173;nal complications include foveal burns, Bruch membrane ruptures, creation of ret&#173;i&#173;nal or choroidal lesions, and exudative choroidal or ret&#173;i&#173;nal detachment. Ret&#173;i&#173;nal nerve fiber layer damage resulting from &#173;laser treatment can have more widespread vision loss than the local area. For example, if the damage occurs in the peripapillary ret&#173;i&#173;nal nerve fiber layer, arcuate scotomas can develop; when the papillomacular bundle is damaged, central vision loss can result.</p>
			<p class="h3 ParaOverride-4">Accidental foveal burns</p>
			<p class="body-text--no-indent-">&#173;Great care should be taken to identify the fovea by means of biomicroscopy; this step may be aided by comparing the appearance with recent fluorescein angiography images. Frequent reference to the foveal center throughout the procedure is helpful to maintain orientation. In some instances, the risk of foveal burns may be reduced by immobilizing the globe with peribulbar or retrobulbar anesthesia, especially when juxtafoveal treatment is being performed.</p>
			<p class="h3 ParaOverride-4">Bruch membrane ruptures</p>
			<p class="body-text--no-indent-">Small spot size, high power, and short duration of applications all increase the risk of a rupture in Bruch membrane, which may subsequently give rise to hemorrhage from the choriocapillaris and development of CNV.</p>
			<p class="h3 ParaOverride-4">Ret&#173;i&#173;nal lesions</p>
			<p class="body-text--no-indent-">Intense photocoagulation may cause full-&#173;thickness ret&#173;i&#173;nal holes. Similarly, intense treatment may create fibrous proliferation, striae, and foveal distortion, with resultant metamorphopsia or diplopia. Focal treatment with small-&#173;diameter, high-&#173;intensity burns may cause vascular occlusion or perforate blood vessels, leading to preret&#173;i&#173;nal or vitreous hemorrhage. In addition, extensive panret&#173;i&#173;nal treatment may induce or exacerbate macular edema, particularly in patients with diabetes mellitus.</p>
			<p class="h3">Choroidal lesions</p>
			<p class="body-text--no-indent-">Treatment of CNV may be complicated by subret&#173;i&#173;nal hemorrhage, choroidal ischemia, and additional CNV or chorioret&#173;i&#173;nal anastomosis. If active subret&#173;i&#173;nal hemorrhage occurs during treatment, it should be addressed immediately by increasing digital pressure on the contact lens while continuing to treat the remaining portions of the CNV lesion in order to minimize obscuration of landmarks by hemorrhage. Progressive atrophy of the RPE may develop at the margin of photocoagulation scars, resulting in enlarged scotomas. Also, photocoagulation may precipitate tears of the pigment epithelium.</p>
			<p class="h3">Exudative ret&#173;i&#173;nal and choroidal detachment</p>
			<p class="body-text--no-indent-">Extensive, intense photocoagulation may lead to massive chorioret&#173;i&#173;nal edema and resultant serous ret&#173;i&#173;nal and choroidal detachment (<span class="xref-figure">Fig 19-3</span>). The latter, in turn, can lead to narrowing of the anterior chamber &#173;angle from forward rotation of the ciliary body, resultant elevated intraocular pressure, and, rarely, aqueous misdirection. This reaction peaks 1–3 days &#173;after treatment and resolves spontaneously within a few weeks. Corticosteroids may be helpful to treat massive exudation.</p>
			<p class="h3">Avoiding &#173;laser photocoagulation complications</p>
			<p class="body-text--no-indent-">As discussed, awareness and avoidance of the fovea during &#173;laser treatment is paramount. Se&#173;lection of proper wavelength, power, exposure time, and spot size is also impor&#173;tant. Proper titration of &#173;laser power and exposure time may be necessary to achieve the desired tissue effect. Waiting for proper pupillary dilation can help limit iris damage. Careful preoperative explanation of the &#173;laser procedure to the patient and comfortable positioning of the patient &#173;will facilitate cooperation and steady fixation, thereby improving safety.</p>
			<p class="reference--journal--single">Palanker D, Lavinsky D, Blumenkranz MS, Marcellino&#160;G. The impact of pulse duration and burn grade on size of ret&#173;i&#173;nal photocoagulation lesion: implications for pattern density. &#173;<span class="italic">Ret&#173;i</span><span class="italic">&#173;na.</span> 2011;31(8):1664–1669.</p>
			</div>
			<p class="h1">Transpupillary Thermotherapy</p>
			<div id="Chapt19_Top2">
			<p class="body-text--no-indent-">Transpupillary thermotherapy (TTT) acts in a subthreshold manner by slightly raising the choroidal temperature, thus causing minimal thermal damage to the RPE and overlying ret&#173;ina. TTT is administered with an infrared &#173;laser (810&#160;nm) using beam sizes from 0.8&#160;mm to 3.0&#160;mm, power settings between 250 mW and 750 mW, and a 1-&#173;minute exposure time. For choroidal melanoma, TTT may be considered as a stand-&#173;alone treatment for tumors less than 4&#160;mm thick, but for thicker tumors, a combination of TTT and plaque radiotherapy results in better local tumor control than TTT alone.</p>
			</div>
			<p class="h1">Photodynamic Therapy</p>
			<div id="Chapt19_Top3">
			<p class="body-text--no-indent-">Photodynamic therapy (PDT) using the photosensitizing drug verteporfin is approved by the US Food and Drug Administration for treating certain types of subfoveal CNV in age-&#173;related macular degeneration and subfoveal CNV that is secondary to ocular histoplasmosis syndrome and myopia. &#173;Because more effective treatments have become available, PDT has generally fallen out of &#173;favor for the management of CNV, but it continues to be a valuable option for the management of some ocular tumors and central serous chorioretinopathy.</p>
			<p class="body-text">PDT is a 2-&#173;step procedure:</p>
			<p class="numbered-list-first">&#9;1.&#9;intravenous administration of the photosensitizing drug, which localizes to endothelial cells of vessels pres&#173;ent in CNV and tumors</p>
			<p class="numbered-list-last">&#9;2.&#9;local activation of the drug by a &#173;laser wavelength preferentially absorbed by the sensitizing drug</p>
			<p class="body-text--no-indent-">The low-&#173;intensity &#173;laser energy produces a photochemical reaction, leading to the formation of reactive oxygen species and &#173;free radicals. &#173;These radicals cause endothelial cell damage, platelet adherence, vascular thrombosis, and capillary closure.</p>
			<p class="h2">Complications of Photodynamic Therapy</p>
			<p class="body-text--no-indent-">The most serious adverse effects of PDT are photosensitivity reactions that range from mild to second-&#173;degree burns of sun-&#173;exposed skin. This can be avoided by having the patient minimize exposure to sunlight for 5 days &#173;after treatment. In the Treatment of Age-&#173;Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group report, severe vision loss occurred in 0.7%–2.2% of patients within 7 days of PDT treatment of subfoveal lesions. Additionally, verteporfin infusion–&#173;related transient lower-&#173;back, side, and chest pain &#173;were reported in 2.0%–2.5% of patients. In efforts to minimize choriocapillaris nonperfusion and ischemia, treatment using half-&#173;fluence PDT (25&#160;J/cm<span class="superscript CharOverride-1">2</span> energy; 300 mW/cm<span class="superscript CharOverride-1">2</span> light intensity) has become more common, and it may be as effective as standard-&#173;fluence PDT.</p>
		</div>
		</div>
		<div id="_idContainer005" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 19-1</span> Absorption spectra of xanthophyll, hemoglobin, and melanin. <span class="figure-source-note">(From Folk JC, </span><span class="figure-source-note">Pulido JS. </span><span class="figure-source-emphasis">Laser Photocoagulation of the Retina and Cho</span><span class="figure-source-emphasis">roid.</span><span class="figure-source-note"> Ophthalmology Monograph 11. San Francisco: Ameri</span><span class="figure-source-note">can Academy of Ophthalmology; 1997:9.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="BCSC1819_S12_C19_p371-380-web-resources/image/AAX-5241.png" alt="" />
			</div>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<table id="table001" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-4" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;19-1</span> Magnification &#173;Factors for Common &#173;Laser Lenses</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-1">
							<p class="table-column-head"><span class="CharOverride-2">Lens</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-1" />
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-1">
							<p class="table-column-head"><span class="CharOverride-2">Magnification</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-1" />
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-1">
							<p class="table-column-head"><span class="CharOverride-2">&#173;Laser Spot Magnification</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-2 _idGenCellOverride-1" colspan="5">
							<p class="table-head">Panret&#173;i&#173;nal photocoagulation lenses</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-body">Ocular Mainster PRP 165</p>
							<p class="table-body">Ocular Mainster Wide Field PDT</p>
							<p class="table-body">Ocular Pro Ret&#173;ina</p>
							<p class="table-body">Rodenstock Panfunduscope</p>
							<p class="table-body">Volk Equator Plus</p>
							<p class="table-body">Volk HR Wide Field</p>
							<p class="table-body">Volk QuadrAspheric</p>
							<p class="table-body">Volk SuperQuad 160</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-3">
							<p class="table-body">0.51<span class="symbol">×</span></p>
							<p class="table-body">0.68<span class="symbol">×</span></p>
							<p class="table-body">0.5<span class="symbol">×</span></p>
							<p class="table-body">0.7<span class="symbol">×</span></p>
							<p class="table-body">0.44<span class="symbol">×</span></p>
							<p class="table-body">0.5<span class="symbol">×</span></p>
							<p class="table-body">0.51<span class="symbol">×</span></p>
							<p class="table-body">0.5<span class="symbol">×</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body" />
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-body ParaOverride-5">1.96<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.5<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">2.0<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.43<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">2.27<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">2.0<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.97<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">2.0<span class="symbol">×</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-9">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" colspan="5">
							<p class="table-head">Focal &#173;laser lenses</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-body">Goldmann 3-&#173;mirror (central)</p>
							<p class="table-body">Ocular Fundus &#173;Laser</p>
							<p class="table-body">Ocular Mainster High Magnification</p>
							<p class="table-body">Ocular PDT 1.6<span class="symbol">×</span></p>
							<p class="table-body">Ocular Reichel-&#173;Mainster 1<span class="symbol">× </span>Ret&#173;ina</p>
							<p class="table-body">Ocular Reichel-&#173;Mainster 2<span class="symbol">× </span>Ret&#173;ina</p>
							<p class="table-body">Ocular Yannuzzi Fundus</p>
							<p class="table-body">Volk Area Centralis</p>
							<p class="table-body">Volk Centralis Direct</p>
							<p class="table-body">Volk Fundus 20</p>
							<p class="table-body">Volk Fundus &#173;Laser</p>
							<p class="table-body">Volk HR Centralis</p>
							<p class="table-body">Volk HR Wide Field</p>
							<p class="table-body">Volk PDT Lens</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-3">
							<p class="table-body">0.93<span class="symbol">×</span></p>
							<p class="table-body">0.93<span class="symbol">×</span></p>
							<p class="table-body">1.25<span class="symbol">×</span></p>
							<p class="table-body">0.63<span class="symbol">×</span></p>
							<p class="table-body">0.95<span class="symbol">×</span></p>
							<p class="table-body">0.5<span class="symbol">×</span></p>
							<p class="table-body">0.93<span class="symbol">×</span></p>
							<p class="table-body">1.06<span class="symbol">×</span></p>
							<p class="table-body">0.9<span class="symbol">×</span></p>
							<p class="table-body">1.44<span class="symbol">×</span></p>
							<p class="table-body">1.25<span class="symbol">×</span></p>
							<p class="table-body">1.08<span class="symbol">×</span></p>
							<p class="table-body">0.5<span class="symbol">×</span></p>
							<p class="table-body">0.66<span class="symbol">×</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body" />
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-body ParaOverride-5">1.08<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.08<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">0.8<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.6<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.05<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">2.0<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.08<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">0.94<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.11<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">0.7<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">0.8<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">0.93<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">2.0<span class="symbol">×</span></p>
							<p class="table-body ParaOverride-5">1.5<span class="symbol">×</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-11">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-5">
							<p class="table-body">Volk SuperMacula 2.2</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-5" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-6">
							<p class="table-body">1.49<span class="symbol">×</span></p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-5" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-5">
							<p class="table-body ParaOverride-5">0.67<span class="symbol">×</span></p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer010">
				<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1819_S12_C19_p371-380-web-resources/image/BTOS_f3701a.png" alt="" />
				</div>
				<div id="_idContainer009" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 19-2</span> Illustration of the posterior extent of full panretinal photocoagulation (peripheral treatment not shown). <span class="figure-source-note">(Illustration by Mark Miller.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer013">
				<div id="_idContainer011" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC1819_S12_C19_p371-380-web-resources/image/AAX-0566.jpg" alt="" />
				</div>
				<div id="_idContainer012" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 19-3</span> Color fundus photograph shows choroidal detachment that occurred following panretinal scatter photocoagulation for diabetic retinopathy. <span class="figure-source-note">(Courtesy of M. Gilbert Grand, MD.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
